Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1762254 | 1.00 | PTGS1 (0.37) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL7648945 | 0.84 | KDM4E (0.39) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL7648952 | 0.84 | KDM4E (0.39) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL29094786 | 0.82 | PTGS1 (0.39) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL197122 | 0.80 | — | — | |
| SCHEMBL197121 | 0.80 | — | — | |
| SCHEMBL8721546 | 0.80 | — | — | |
| SCHEMBL1984019 | 0.79 | PTGS1 (0.37) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL1984021 | 0.79 | PTGS1 (0.37) | PTGS1SLC7A11KDM4EMAPTTHRB | |
| SCHEMBL10786181 | 0.79 | PTGS1 (0.37) | PTGS1SLC7A11KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1276732-B1 | AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION\ | DOMPE PHA R MA SPA RES & MFG (IT) | 2007-09-26 | — | — | EP | claimed |
| US-7217707-B2 | Amide of R-2-(aminoaryl)-propionic acid for use in the prevention of leucocyte activation | DOMPE S.P.A. (IT) | 2007-05-15 | — | — | US | claimed |
| US-20040186146-A1 | Amide of r-2-(aminoaryl)-propionic acid for use in theprevention of leucocyte activation | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-09-23 | — | — | US | claimed |
| EP-1276732-A1 | AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION\ | Dompé S.P.A. (IT) | 2003-01-22 | — | — | EP | claimed |
| WO-2001079189-A2 | 'AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION' | Dompé S.p.A. (IT) | 2001-10-25 | — | — | WO | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| JP-8020599-A | — | — | None | — | — | JP | disclosed |
| US-20260008997-A1 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | GENENTECH, INC. (US) | 2026-01-08 | — | — | US | disclosed |
| EP-2970875-B2 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | disclosed |
| US-20210017488-A1 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | GENENTECH, INC. (US) | 2021-01-21 | — | — | US | disclosed |
| US-10829732-B2 | Cell culture compositions with antioxidants and methods for polypeptide production | GENENTECH, INC. (US) | 2020-11-10 | — | — | US | disclosed |
| EP-3712252-A1 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | F. Hoffmann-La Roche AG (CH) | 2020-09-23 | — | — | EP | disclosed |
| WO-2000059500-A1 | SWALLOWABLE TABLETS WITH HIGH CONTENT OF N-ACETYLCYSTEINE | ZAMBON GROUP S.P.A. (IT) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000023081-A1 | DERIVATIVES OF ERYTHROMYCIN, CLARITHROMYCIN, ROXITHROMYCIN OR AZITHROMYCIN WITH ANTIBIOTIC AND MUCOLYTIC ACTIVITY | LAUTERAL LIMITED (IE) | 2000-04-27 | — | — | WO | disclosed |
| JP-H0820599-A | NEW PROTEIN | MITSUBISHI CHEM CORP | 1996-01-23 | — | — | JP | disclosed |
| EP-0422339-A1 | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same | AMGEN BOULDER INC. (US) | 1991-04-17 | — | — | EP | disclosed |
| EP-0233973-A1 | Mixture of amino acid derivatives, process of producing the mixture and use of the mixture for quantitative determination of the amino acids | Hewlett-Packard GmbH (DE) | 1987-09-02 | — | — | EP | disclosed |
| US-4217914-A | Quaternized polymer for use as a cosmetic agent in cosmetic compositions for the hair and skin | L'OREAL (FR) | 1980-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008997-A1 | CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION | CD99, BHMT, PROC | PTGS1 2121/4885SLC7A11 180/4885KDM4E 1952/4885 |
| US-20040186146-A1 | Amide of r-2-(aminoaryl)-propionic acid for use in theprevention of leucocyte activation | MMP8, CXCL8, HCAR2 | PTGS1 370/4885SLC7A11 2076/4885KDM4E 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.